

David W Mudge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4364880/publications.pdf>

Version: 2024-02-01

80
papers

5,361
citations

147566

31
h-index

82410

72
g-index

80
all docs

80
docs citations

80
times ranked

6164
citing authors

#	ARTICLE	IF	CITATIONS
1	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	6.3	2,087
2	Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. <i>New England Journal of Medicine</i> , 2014, 370, 13-22.	13.9	804
3	Randomized, Controlled Trial of Topical Exit-Site Application of Honey (Medihoney) versus Mupirocin for the Prevention of Catheter-Associated Infections in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1456-1462.	3.0	135
4	Predictors of Decline of Residual Renal Function in New Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 276-283.	1.1	130
5	Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 486-497.	2.1	115
6	Free Mycophenolic Acid Should Be Monitored in Renal Transplant Recipients with Hypoalbuminemia. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 284-286.	1.0	108
7	Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. <i>Nephrology</i> , 2007, 12, 391-398.	0.7	102
8	Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 271-280.	1.1	97
9	Altered dietary salt intake for people with chronic kidney disease. <i>The Cochrane Library</i> , 2015, , CD010070.	1.5	96
10	Peritoneal dialysis practice in Australia and New Zealand: A call to action. <i>Nephrology</i> , 2011, 16, 19-29.	0.7	74
11	A Randomized Controlled Trial of Coiled Versus Straight Swan-Neck Tenckhoff Catheters in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 48, 812-821.	2.1	71
12	Automated and continuous ambulatory peritoneal dialysis have similar outcomes. <i>Kidney International</i> , 2008, 73, 480-488.	2.6	68
13	The impact of automated eGFR reporting and education on nephrology service referrals. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3845-3850.	0.4	68
14	Predictors of decline of residual renal function in new peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 276-83.	1.1	66
15	Intradermal Versus Intramuscular Hepatitis B Vaccination in Hemodialysis Patients: A Prospective Open-Label Randomized Controlled Trial in Nonresponders to Primary Vaccination. <i>American Journal of Kidney Diseases</i> , 2009, 54, 95-103.	2.1	63
16	The impact of extended 6-hour home hemodialysis and buttonhole cannulation technique on hospitalization rates for septic events related to dialysis access. <i>Hemodialysis International</i> , 2010, 14, 451-463.	0.4	61
17	Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 799, 157-163.	1.2	54
18	Phosphate binders in patients with chronic kidney disease. <i>Australian Prescriber</i> , 2017, 40, 9-14.	0.5	54

#	ARTICLE	IF	CITATIONS
19	Severe Toxicity Associated with a Markedly Elevated Mycophenolic Acid Free Fraction in a Renal Transplant Recipient. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 453-455.	1.0	48
20	Achieving Salt Restriction in Chronic Kidney Disease. <i>International Journal of Nephrology</i> , 2012, 2012, 1-10.	0.7	43
21	Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?. <i>BMC Nephrology</i> , 2011, 12, 20.	0.8	42
22	Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. <i>Nephrology</i> , 2012, 17, 42-47.	0.7	42
23	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 776-783.	0.4	41
24	Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. <i>The Cochrane Library</i> , 2017, 2017, CD004679.	1.5	41
25	The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. <i>Transplantation</i> , 2004, 77, 206-209.	0.5	40
26	Quality of life and alternate nightly nocturnal home hemodialysis. <i>Hemodialysis International</i> , 2010, 14, 29-38.	0.4	39
27	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1530-1539.	0.4	38
28	Prevention of peritoneal dialysis-related infections. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1461-1472.	0.4	37
29	A Comparison of Peritoneal Equilibration Tests Performed 1 and 4 Weeks after PD Commencement. <i>Peritoneal Dialysis International</i> , 2004, 24, 460-465.	1.1	36
30	Cutaneous manifestations of cytomegalovirus disease in renal transplant recipients: a case series. <i>Transplant Infectious Disease</i> , 2008, 10, 209-213.	0.7	36
31	Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. <i>Nephrology</i> , 2007, 12, 224-233.	0.7	35
32	A Randomized Controlled Trial of Intravenous or Oral Iron for Posttransplant Anemia in Kidney Transplantation. <i>Transplantation</i> , 2012, 93, 822-826.	0.5	33
33	A Randomized Controlled Trial of Fludrocortisone for the Treatment of Hyperkalemia in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 47, 809-814.	2.1	30
34	Altered dietary salt intake for people with chronic kidney disease. <i>The Cochrane Library</i> , 2021, 2021, CD010070.	1.5	30
35	Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. <i>Transplant International</i> , 2007, 20, 64-72.	0.8	29
36	Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action. <i>Nephrology</i> , 2016, 21, 535-546.	0.7	29

#	ARTICLE	IF	CITATIONS
37	Patients' Perspectives on the Prevention and Treatment of Peritonitis in Peritoneal Dialysis: A Semi-Structured Interview Study. <i>Peritoneal Dialysis International</i> , 2016, 36, 631-639.	1.1	28
38	Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. <i>BMC Nephrology</i> , 2017, 18, 281.	0.8	25
39	A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4146-4153.	0.4	24
40	Coca-Cola and kangaroos. <i>Lancet</i> , The, 2004, 364, 1190.	6.3	19
41	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2015, 35, 222-228.	1.1	19
42	Human SLC26A1 Gene Variants: A Pilot Study. <i>Scientific World Journal</i> , The, 2013, 2013, 1-7.	0.8	18
43	Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus Ethanol Lock Therapy for the prevention of Catheter Associated Infection in Haemodialysis patients. <i>BMC Nephrology</i> , 2009, 10, 23.	0.8	17
44	KHA-CARI Guideline: Peritonitis treatment and prophylaxis. <i>Nephrology</i> , 2014, 19, 69-71.	0.7	17
45	Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 619-627.	0.4	17
46	Paracetamol and asthma. <i>Thorax</i> , 2000, 55, 882-882.	2.7	16
47	Induction and maintenance therapy in ANCA-associated systemic vasculitis. <i>Nephrology</i> , 2008, 13, S24-36.	0.7	16
48	Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. <i>BMC Nephrology</i> , 2009, 10, 29.	0.8	16
49	A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. <i>AIDS Research and Therapy</i> , 2014, 11, 35.	0.7	16
50	Deceased donor renal transplantation—does side matter?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2583-2588.	0.4	15
51	Pharmacokinetics and normal scintigraphic appearance of 99mTc aprotinin. <i>Nuclear Medicine Communications</i> , 2005, 26, 535-539.	0.5	14
52	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 397-406.	1.1	14
53	Methamphetamine intoxication and acute kidney injury: A prospective observational case series. <i>Nephrology</i> , 2020, 25, 758-764.	0.7	14
54	Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2178-2185.	0.4	11

#	ARTICLE	IF	CITATIONS
55	Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients. BMC Nephrology, 2009, 10, 14.	0.8	11
56	Hepatic vein stenting for recurrent ascites in polycystic liver and kidney disease. Nephrology Dialysis Transplantation, 2005, 20, 2566-2568.	0.4	10
57	Life-threatening adenovirus infection in a kidney transplant recipient. CKJ: Clinical Kidney Journal, 2009, 2, 250-253.	1.4	10
58	Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study. BMC Nephrology, 2011, 12, 51.	0.8	10
59	Change in live donor characteristics over the last 25 years: A single centre experience. Nephrology, 2008, 13, 646-650.	0.7	9
60	Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT) Tj ETQq0 0 0 rg88 /Overlock 10 Tf 5	0.8	10
61	Effect of FX Dialysers on Systemic Inflammation and Quality of Life in Chronic Haemodialysis Patients. Blood Purification, 2009, 27, 187-193.	0.9	8
62	Infection Prophylaxis in Peritoneal Dialysis Patients: Results from an Australia/New Zealand Survey. Peritoneal Dialysis International, 2017, 37, 191-197.	1.1	7
63	Hydralazine-induced anti-neutrophil cytoplasmic antibody-positive renal vasculitis presenting with a vasculitic syndrome, acute nephritis and a puzzling skin rash: a case report. Journal of Medical Case Reports, 2013, 7, 20.	0.4	6
64	Pro: Meta-analysis: the case<i>for</i>. Nephrology Dialysis Transplantation, 2016, 31, 875-880.	0.4	6
65	Baseline characteristics of patients with atypical haemolytic uraemic syndrome (aHUS): The Australian cohort in a global aHUS registry. Nephrology, 2020, 25, 683-690.	0.7	6
66	Iron Therapy in Renal Transplant Recipients. Transplantation, 2004, 78, 1239-1240.	0.5	5
67	Altered dietary salt intake for chronic kidney disease. , 2012, , .		5
68	Avoiding or stopping steroids in kidney transplant recipients: sounds good but does it work?. , 2016, 8, ED000114.		4
69	Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report. Journal of Medical Case Reports, 2010, 4, 276.	0.4	3
70	Pancreatic and biliary obstruction years after retention of a swallowed coin in a duodenal diverticulum: a case report. Journal of Medical Case Reports, 2015, 9, 144.	0.4	3
71	Temporal Changes in Deceased Kidney Donor Characteristics in Australia. Transplantation Direct, 2016, 2, e112.	0.8	3
72	Obliterative bronchiolitis or opportunistic infection? A diagnostic challenge in a renal transplant patient. Nephrology Dialysis Transplantation, 2005, 20, 246-247.	0.4	2

#	ARTICLE	IF	CITATIONS
73	DABIGATRAN MAY NOT BE AN EFFECTIVE ANTICOAGULANT FOR HAEMODIALYSIS. <i>Nephrology</i> , 2010, 15, 594-595.	0.7	2
74	Kidney transplantation without reversal of warfarin. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 170-171.	1.4	1
75	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 885-886.	0.4	1
76	Recurrent atypical haemolytic uraemic syndrome post kidney transplant due to aCD46mutation in the setting ofSMARCAL1-mediated inherited kidney disease. <i>Nephrology</i> , 2017, 22, 11-14.	0.7	1
77	Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient. <i>Case Reports in Transplantation</i> , 2017, 2017, 1-4.	0.1	1
78	Response: Iron Therapy in Renal Transplant Recipients. <i>Transplantation</i> , 2004, 78, 1240.	0.5	0
79	Interventions for post-transplant anaemia in kidney transplant recipients. <i>The Cochrane Library</i> , 0, , .	1.5	0
80	Utility of "back-to-back" arteriovenous fistulae in patients on peritoneal dialysis and use of haemodialysis catheters. <i>Internal Medicine Journal</i> , 2020, 51, 1106-1110.	0.5	0